According to data published in the Journal of Clinical Oncology, adding Sutent to therapy for patients with HER-2–negative breast cancer did not extend patient survival.
In the Phase III study, almost 600 patients were assigned at random to one of two arms:
-- 37.5 mg daily sunitinib (Sutent) plus 75 mg/m2 docetaxel once every 3 weeks
-- 100 mg/m2 docetaxel once every 3 weeks
Results were disappointing: Sutent plus docetaxel failed to extend progression free survival or overall survival compared to docetaxel alone.
More patients in the combination arm died (107 vs 91) and patients in that arm also experienced adverse events more frequently.
Source: HemOncToday
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
